Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates mixed signals: improved backlog growth and low cancellations are positive, but the weak win rate and dependency on low cancellations for future success are concerning. The Q&A reveals management's reluctance to provide specific long-term guidance, adding uncertainty. Despite improved productivity and revenue growth, reliance on pass-through revenue and potential headwinds in 2025 suggest caution. These factors, combined with management's vague responses, lead to a neutral sentiment, anticipating minimal stock price movement.
Key Financial Performance
Revenue Revenue for the second quarter of 2025 was $603.3 million, representing a year-over-year increase of 14.2%. The increase was driven by higher reimbursable activity, particularly at investigator sites, due to studies progressing ahead of projected schedules and a therapeutic mix shift to faster burning studies in areas like metabolic, which have a higher concentration of reimbursable costs.
Net New Business Awards Net new business awards entering backlog in the second quarter increased 12.6% from the prior year to $620.5 million, resulting in a 1.03x net book-to-bill.
Ending Backlog Ending backlog as of June 30, 2025, was approximately $2.9 billion, a decrease of 1.8% from the prior year.
EBITDA EBITDA of $130.5 million increased by 16.2% compared to $112.3 million in the second quarter of 2024. On a constant currency basis, second quarter EBITDA increased 18.5%. The increase was attributed to direct service activities and productivity, offset by higher reimbursable costs and foreign exchange losses due to a weaker U.S. dollar.
EBITDA Margin EBITDA margin for the second quarter was 21.6% compared to 21.3% in the prior year period. The margin benefited from direct service activities and productivity but was offset by higher reimbursable costs and foreign exchange losses.
Net Income Net income of $90.3 million increased 2.2% compared to $88.4 million in the prior year period. The growth was primarily driven by EBITDA growth, offset by a higher effective tax rate and lower interest income.
Net Income Per Diluted Share Net income per diluted share for the quarter was $3.10 compared to $2.75 in the prior year period.
Cash Flow from Operating Activities In the second quarter, $148.5 million was generated in cash flow from operating activities.
Share Repurchases During the second quarter, approximately 1.75 million shares were repurchased for $518.5 million. Year-to-date, 2.9 million shares were repurchased for $908.4 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue Growth: Revenue for Q2 2025 was $603.3 million, a 14.2% year-over-year increase. Full-year 2025 revenue is projected to grow by 14.7% to 19.5% compared to 2024.
Backlog Conversion: Backlog conversion in Q2 2025 was 21.2%, with $1.75 billion of backlog expected to convert to revenue in the next 12 months.
Operational Efficiency: Revenue growth was driven by higher reimbursable activity, particularly at investigator sites, and a shift to faster-burning therapeutic areas like metabolic studies.
EBITDA Growth: EBITDA for Q2 2025 was $130.5 million, a 16.2% increase year-over-year, with a margin of 21.6%.
Therapeutic Area Shift: Shifted focus from oncology to faster-burning therapeutic areas like metabolic studies, which have higher reimbursable costs.
Share Repurchase Program: Repurchased 1.75 million shares for $518.5 million in Q2 2025, with $826.3 million remaining under the authorization program.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Funding Challenges: Funding challenges remain acute for many clients, though most have managed to secure sufficient funding to keep trials running. This could impact the company's ability to maintain consistent operations if funding issues worsen.
Backlog Decrease: Ending backlog as of June 30, 2025, decreased by 1.8% from the prior year, which could indicate potential challenges in securing future business.
Customer Concentration Risk: The top 5 and top 10 customers represent 21% and 31% of year-to-date revenue, respectively. This high concentration poses a risk if any of these customers reduce or terminate their engagements.
Foreign Exchange Losses: EBITDA margin was negatively impacted by foreign exchange losses due to a weaker U.S. dollar, which could continue to affect profitability if currency fluctuations persist.
Higher Investigator Costs: Significantly higher investigator costs were noted, which could pressure margins and impact financial performance if not managed effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Full year 2025 total revenue is expected in the range of $2.42 billion to $2.52 billion, representing growth of 14.7% to 19.5% over 2024 total revenue of $2.11 billion. Revenue guidance has been raised by $280 million at the midpoint due to better funding, fewer cancellations, and a shift toward faster burning therapeutic areas.
EBITDA Guidance: 2025 EBITDA is expected in the range of $515 million to $545 million, representing growth of 7.3% to 13.5% compared to EBITDA of $480.2 million in 2024.
Net Income Guidance: 2025 net income is forecasted in the range of $405 million to $428 million, with an effective tax rate of 18.5% to 19%.
Earnings Per Share (EPS) Guidance: Earnings per diluted share for 2025 is expected to be in the range of $13.76 to $14.53.
Backlog Conversion: Approximately $1.75 billion of backlog is projected to convert to revenue in the next 12 months.
Reimbursable Costs: Reimbursable costs as a percentage of revenue are expected to increase by 200 to 300 basis points over the balance of the year.
Market Trends and Business Mix: The business is shifting away from oncology and toward faster burning therapeutic areas like metabolic studies, which have a higher concentration of reimbursable costs. This shift is expected to accelerate revenue in the second half of 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: During the second quarter, we repurchased approximately 1.75 million shares for $518.5 million. Year-to-date, we repurchased 2.9 million shares for $908.4 million. As of June 30, 2025, we had $826.3 million remaining under our share repurchase authorization program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the booking expectations for the second half of the year, and how does it relate to 2026 revenue growth?
A:Management expects bookings to increase in the second half of the year, with a reasonable chance of achieving a book-to-bill ratio over 1.15x. This implies a considerable increase in bookings, which is expected to support 2026 revenue growth. However, this is dependent on cancellations remaining low.
Q:Can you provide more information on cancellations?
A:Management does not disclose the actual cancellation rate but noted that cancellations were down across the entire portfolio in Q2. Backlog cancellations were at the lower end of expectations, contributing to better-than-expected bookings, revenue, and EBITDA performance.
Q:How much of the increased guidance is due to pass-through revenue versus direct revenue?
A:A large portion of the increased guidance is due to accelerated reimbursable cost activity, with pass-throughs expected to be 200 to 300 basis points higher over the balance of the year. There is also some pull-through from greater staff productivity and programs progressing ahead of schedule.
Q:How is management able to achieve additional productivity from staff, and what are the hiring expectations?
A:Management has seen improved attrition rates and reduced hiring expectations. They expect some headwinds in 2025 relative to 2024 but have seen improved productivity from existing staff. Hiring is expected to accelerate in the second half of the year to support revenue growth and bookings expectations.
Q:How does management view the weak funding environment and its impact on demand activity?
A:Management acknowledges the weak funding environment but notes that cancellations have been the primary challenge over the past year. They have a good pipeline of awarded projects not yet in backlog, which should support bookings through the remainder of the year, provided cancellations remain low.
Q:How did intra-quarter trends evolve in Q2, and what was the demand environment like?
A:Q2 was a continuation of Q1, with a strong business environment for RFPs. Cancellations were low throughout the quarter, which was a significant improvement compared to prior quarters. There were no notable trends of acceleration or deceleration within the quarter.
Q:Are there any changes in the scope of delayed or new trials, and how does this impact EBITDA margins?
A:Some projects have been downscoped, which is common in any environment. Delays and downscoping can impact profitability, as faster-running projects are more profitable. However, there is no indication that downscoping was particularly prevalent in Q2.
Q:What are the expectations for book-to-bill in the back half of the year, and what factors could impact this?
A:Management aims to achieve a book-to-bill ratio of 1.15x in the back half of the year, which would imply bookings up more than 40% year-over-year. This depends on cancellations remaining low and the absence of significant macroeconomic deterioration.
Q:What was the win rate in Q2, and how does it reflect competitive dynamics?
A:The win rate in Q2 was lower than usual, primarily due to the loss of a few very large projects. However, the overall number of decisions increased, and awards were strong. Management does not see this as a trend and attributes it to normal quarter-to-quarter variability.
Q:What is the outlook for pass-through revenue in the back half of the year and beyond?
A:Pass-through revenue is expected to remain elevated in the near term, with a 200 to 300 basis point increase over Q2 levels. Management is not providing guidance for 2026 but expects the elevated levels to continue for the remainder of the year.
Q:How does management view the sustainability of current growth rates and backlog conversion?
A:Management acknowledges the faster burn rates and elevated backlog conversion due to a shift toward faster-burning therapeutic areas like metabolic studies. They believe growth rates are sustainable in the near term, provided cancellations remain low and the business environment remains stable.
Q:What are the hiring expectations for the second half of the year?
A:Hiring is expected to accelerate in the second half of the year, with full-year headcount growth projected at 5% to 6%. This is to support the elevated burn rates and revenue growth.
Q:What is the impact of cancellations on the business, and how has this trended?
A:Cancellations have been a significant challenge over the past year, with Q1 seeing very high levels. However, Q2 saw a significant improvement, with cancellations at the lower end of expectations. This contributed to better-than-expected bookings and revenue.
Q:What is the exposure to cell and gene therapy, and has there been any impact from recent industry developments?
A:Management has limited exposure to cell and gene therapy and noted no impact from recent developments, such as Sarepta's clinical trial issues.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026 revenue growth, stating that it depends on future bookings and cancellations. They also did not disclose the actual cancellation rate or provide detailed commentary on the sustainability of elevated pass-through revenue levels beyond the near term.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AG Research
Aaron Cherny
Ann Kathleen
Associate Director
Baird Co
Bank AG
Bank PLC
Bank Research
Barclays Bank
Blair LLC
Brady CFO
Brady SEC
CEO Geiger
CFO Treasurer
Cancellations award
Chairman CEO
Cherny Leerink
Co Incorporated
Conference reminder
Cowen Research
Crews UBS
Director Investors
Division Aaron
Division Conference
Division Eric
Division Howard
Division Jailendra
Division Justin
Division Kyle
LLC Research
Medpace Conference
Research Division
Troendle
decision
MEDP Transcript
Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript
Unknown2-10
The earnings call presented a mixed picture: strong revenue growth expectations were offset by high cancellation rates and unclear management responses on key issues like AI impact and M&A environment. While product development and market strategy showed some positive signs, concerns over pass-through costs and the lack of specific guidance on cancellation trends and burn rate create uncertainties. The absence of a new partnership announcement or major shareholder return plan further tempers positive sentiment, resulting in a neutral outlook for the stock price over the next two weeks.
Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript
Positive10-23
The earnings call summary indicates strong revenue guidance with a raised outlook, optimistic backlog conversion, and a strategic shift to faster growing therapeutic areas. Despite slower EBITDA growth, the overall sentiment is positive due to improved funding confidence, a strong pre-backlog position, and expected acceleration in hiring. While some uncertainties remain, particularly around cancellations and competition, the positive aspects outweigh them, suggesting a likely stock price increase over the next two weeks.
Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript
Unknown7-22
The earnings call summary indicates mixed signals: improved backlog growth and low cancellations are positive, but the weak win rate and dependency on low cancellations for future success are concerning. The Q&A reveals management's reluctance to provide specific long-term guidance, adding uncertainty. Despite improved productivity and revenue growth, reliance on pass-through revenue and potential headwinds in 2025 suggest caution. These factors, combined with management's vague responses, lead to a neutral sentiment, anticipating minimal stock price movement.
Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2025 Earnings Call Transcript
Unknown4-23
The earnings call reveals concerns about increased price competition, mixed project quality, and reliance on a few customers. EBITDA margins are decreasing, and there is uncertainty in backlog growth and bookings due to cancellations. Despite share repurchases, the Q&A highlights risks like funding issues and lack of clear guidance. These factors, combined with a decrease in net new business awards, suggest a negative sentiment likely affecting stock price.
MEDP Slides
MEDP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
